tradingkey.logo

Bluejay Diagnostics Inc

BJDX
3.390USD
+0.415+13.95%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
1.39MMarktkapitalisierung
VerlustKGV TTM

Bluejay Diagnostics Inc

3.390
+0.415+13.95%

mehr Informationen über Bluejay Diagnostics Inc Unternehmen

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.

Bluejay Diagnostics Inc Informationen

BörsenkürzelBJDX
Name des UnternehmensBluejay Diagnostics Inc
IPO-datumNov 10, 2021
CEODey (Neil)
Anzahl der mitarbeiter7
WertpapierartOrdinary Share
GeschäftsjahresendeNov 10
Addresse360 Massachusetts Avenue, Suite 203
StadtACTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01720
Telefon19786310152
Websitehttps://bluejaydx.com/
BörsenkürzelBJDX
IPO-datumNov 10, 2021
CEODey (Neil)

Führungskräfte von Bluejay Diagnostics Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
25.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
2.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
25.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
2.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--

Umsatzaufteilung

FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Fri, Jan 30
Aktualisiert: Fri, Jan 30
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Intracoastal Capital, L.L.C.
6.17%
DRW Securities, LLC
2.11%
Sabby Management, LLC
1.05%
Geode Capital Management, L.L.C.
0.36%
Armistice Capital LLC
0.25%
Andere
90.06%
Aktionäre
Aktionäre
Anteil
Intracoastal Capital, L.L.C.
6.17%
DRW Securities, LLC
2.11%
Sabby Management, LLC
1.05%
Geode Capital Management, L.L.C.
0.36%
Armistice Capital LLC
0.25%
Andere
90.06%
Aktionärstypen
Aktionäre
Anteil
Corporation
6.19%
Investment Advisor
2.20%
Investment Advisor/Hedge Fund
1.41%
Hedge Fund
0.40%
Individual Investor
0.02%
Andere
89.77%

Institutionelle Beteiligung

Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
21
107.69K
6.48%
--
2025Q3
22
107.69K
7.87%
-5.14K
2025Q2
22
108.63K
1.16%
+96.42K
2025Q1
23
12.21K
4.22%
-11.19K
2024Q4
24
12.14K
4.03%
-17.82K
2024Q3
26
29.96K
1.04%
+23.88K
2024Q2
26
6.08K
2.15%
+5.00K
2024Q1
24
1.08K
7.93%
+549.00
2023Q4
24
499.00
2.34%
+441.00
2023Q3
25
58.00
1.55%
+36.00
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Intracoastal Capital, L.L.C.
175.00K
9.65%
+175.00K
--
Oct 16, 2025
DRW Securities, LLC
59.77K
3.29%
+59.77K
--
Sep 30, 2025
Sabby Management, LLC
29.63K
1.63%
-66.41K
-69.15%
Sep 30, 2025
Geode Capital Management, L.L.C.
4.20K
0.23%
--
--
Nov 30, 2025
Armistice Capital LLC
6.95K
0.38%
+6.95K
--
Sep 30, 2024
Tower Research Capital LLC
4.45K
0.25%
+2.18K
+95.77%
Sep 30, 2025
L1 Global Manager Pty Limited
2.68K
0.15%
+2.68K
--
Jun 27, 2024
Lana Management & Business Research International LLC
511.00
0.03%
--
--
May 02, 2025
Wurth (Douglas Clark)
414.00
0.02%
--
--
May 02, 2025
Chase (Donald R)
98.00
0.01%
--
--
May 02, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Jan 27, 2026
Merger
4→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Datum
Ex-Dividendentag
Art
Verhältnis
Jan 27, 2026
Merger
4→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jul 21, 2023
Merger
20→1
Mehr Anzeigen
KeyAI